Patents by Inventor Daniel John Lightwood

Daniel John Lightwood has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11174311
    Abstract: It has been demonstrated that certain compounds bind to TNF and stabilise a conformation of trimeric TNF that binds to the TNF receptor. Antibodies which selectively bind to complexes of such compounds with TNF superfamily members are disclosed. These antibodies may be used to detect further compounds with the same activity, and as target engagement biomarker.
    Type: Grant
    Filed: December 13, 2017
    Date of Patent: November 16, 2021
    Assignees: UCB BIOPHARMA SRL, SANOFI
    Inventors: Alastair David Griffiths Lawson, Daniel John Lightwood, Rebecca Jayne Munro, James Philip O'Connell, John Robert Porter
  • Publication number: 20210262024
    Abstract: The present disclosure relates to a duplex probe molecule comprising: i) a double-stranded-core (the core) comprising a first polynucleotide strand (first-strand) and a second polynucleotide strand (second-strand), wherein the first and second strands are complementary to each other, ii) a single stranded first polynucleotide probe (first probe) sequence extending in the 5? to 3? direction from the first-strand of the core; and iii) single stranded second polynucleotide probe (second probe) sequence extending in the 5? to 3? direction from the second strand of the core; wherein the first and second probes extend outwards from the double stranded core in opposing directions on different polynucleotide strands and each terminate in a 3? end. The disclosure also extends to methods of making the molecule and use of the molecule, for example to capture variable domains sequence information from antibodies.
    Type: Application
    Filed: July 3, 2019
    Publication date: August 26, 2021
    Inventors: Daniel John LIGHTWOOD, Michael John WRIGHT
  • Patent number: 11091542
    Abstract: The invention relates to antibody molecules having specificity for TNF alpha, therapeutic uses of the antibody molecules and methods for producing said antibody molecules.
    Type: Grant
    Filed: December 14, 2016
    Date of Patent: August 17, 2021
    Assignee: UCB BIOPHARMA SRL
    Inventors: Ralph Adams, Pallavi Bhatta, Emma Dave, Sam Philip Heywood, David Paul Humphreys, Diane Marshall, Daniel John Lightwood
  • Patent number: 11022614
    Abstract: It has been demonstrated that certain compounds bind to TNF and stabilise a conformation of trimeric TNF that binds to the TNF receptor. Antibodies which selectively bind to complexes of such compounds with TNF superfamily members are disclosed. These antibodies may be used to detect further compounds with the same activity, and as target engagement biomarker.
    Type: Grant
    Filed: October 22, 2015
    Date of Patent: June 1, 2021
    Assignee: UCB Biopharma SRL
    Inventors: James Philip O'Connell, John Robert Porter, Alastair Lawson, Tracy Lynn Arakaki, Daniel John Lightwood, Rebecca Jayne Munro
  • Publication number: 20210132079
    Abstract: It has been demonstrated that certain compounds bind to TNF and stabilise a conformation of trimeric TNF that binds to the TNF receptor. Antibodies which selectively bind to complexes of such compounds with TNF superfamily members are disclosed. These antibodies may be used to detect further compounds with the same activity, and as target engagement biomarker.
    Type: Application
    Filed: January 7, 2021
    Publication date: May 6, 2021
    Inventors: James Philip O'CONNELL, John Robert PORTER, Alastair LAWSON, Daniel John LIGHTWOOD, Rebecca Jayne MUNRO
  • Publication number: 20210107971
    Abstract: The present invention relates to antibodies binding alpha synuclein and fragments thereof capable of binding alpha synuclein as a monomer and in fibrils and preventing alpha synuclein aggregation induced by alpha synuclein fibrils. The antibodies of the present invention are for use in the treatment of alpha synucleinopathies, including Parkinson's disease.
    Type: Application
    Filed: December 13, 2018
    Publication date: April 15, 2021
    Inventors: Ralph ADAMS, Patrick DOWNEY, Terence Seward BAKER, Kerry Louise TYSON, Lorenzo DE LICHTERVELDE, Daniel John LIGHTWOOD, David James MCMILLAN
  • Publication number: 20210101964
    Abstract: The present invention relates to alpha synuclein binding antibodies and fragments thereof capable of binding alpha synuclein as a monomer and in fibrils and preventing alpha synuclein aggregation induced by alpha synuclein fibrils. The antibodies of the present invention are for use in the treatment of alpha synucleinopathies, including Parkinson's disease.
    Type: Application
    Filed: December 13, 2018
    Publication date: April 8, 2021
    Inventors: Patrick DOWNEY, Kerry Louise TYSON, Marco KRIEK, Lorenzo DE LICHTERVELDE, Daniel John LIGHTWOOD, David James MCMILLAN, Peter Charles ELLIOTT, Terence Seward BAKER
  • Patent number: 10969393
    Abstract: It has been demonstrated that certain compounds bind to TNF and stabilise a conformation of trimeric TNF that binds to the TNF receptor. Antibodies which selectively bind to complexes of such compounds with TNF superfamily members are disclosed. These antibodies may be used to detect further compounds with the same activity, and as target engagement biomarker.
    Type: Grant
    Filed: October 22, 2015
    Date of Patent: April 6, 2021
    Assignee: UCB Biopharma SRL
    Inventors: James Philip O'Connell, John Robert Porter, Alastair Lawson, Daniel John Lightwood, Rebecca Jayne Munro
  • Publication number: 20210088530
    Abstract: A new, stable trimeric TNF? structure is disclosed with distorted symmetry which can bind to the TNFR1 receptor to attenuate signalling therefrom, which can be used in the treatment and/or prevention of diseases associated with the soluble TNF?/TNFR1 interaction. Membrane-bound TNF? is not affected in its ability to signal through TNFR2, and thus the new structure of TNF? may be used in therapies which do not significantly raise the risk of infection or malignancy.
    Type: Application
    Filed: September 4, 2020
    Publication date: March 25, 2021
    Inventors: James Philip O'CONNELL, John Robert PORTER, Alastair LAWSON, Boris KROEPLIEN, Stephen Edward RAPECKI, Timothy John NORMAN, Graham John WARRELLOW, Tracy Lynn ARAKAKI, Alex Buntin BURGIN, William Ross PITT, Mark Daniel CALMIANO, David Andreas SCHUBERT, Daniel John LIGHTWOOD, Rebecca Jayne MUNRO
  • Patent number: 10935553
    Abstract: It has been demonstrated that certain compounds bind to TNF and stabilise a conformation of trimeric TNF that binds to the TNF receptor. Antibodies which selectively bind to complexes of such compounds with TNF superfamily members are disclosed. These antibodies may be used to detect further compounds with the same activity, and as target engagement biomarker.
    Type: Grant
    Filed: October 22, 2015
    Date of Patent: March 2, 2021
    Assignee: UCB Biopharma SRL
    Inventors: James Philip O'Connell, John Robert Porter, Alastair Lawson, Daniel John Lightwood, Rebecca Jayne Munro
  • Publication number: 20200407436
    Abstract: The present disclosure relates to TGF-beta antibodies and binding fragments thereof, DNA encoding the same, host cells comprising said DNA and methods of expressing the antibody or binding fragment in a host cell. The disclosure also extends to pharmaceutical compositions comprising the antibody or a binding fragment thereof and use of the antibody, binding fragment and compositions comprising the same in treatment of various diseases including fibrosis.
    Type: Application
    Filed: July 9, 2020
    Publication date: December 31, 2020
    Inventors: Helene BON, Joanne Elizabeth COMPSON, Kate Louise DIXON, Carl Brendan DOYLE, Mark ELLIS, Maria Margarida GOUVEIA SANCHO, Raymond Anthony JUPP, Lara KEVORKIAN, Daniel John LIGHTWOOD, Diane MARSHALL, Andrew Charles PAYNE, Joseph Michael David RASTRICK, Monika-Sarah SCHULZE, Alison TURNER, Kerry Louise TYSON
  • Publication number: 20200377578
    Abstract: This present invention describes the derivation and selection of antibodies capable of neutralising the major exotoxins; TcdA and TcdB of Clostridium difficile. The invention also describes novel neutralisation and antigen binding properties of individual Mabs and mixtures thereof.
    Type: Application
    Filed: July 2, 2020
    Publication date: December 3, 2020
    Applicant: UCB Biopharma SPRL
    Inventors: David Paul Humphreys, Daniel John Lightwood, Kerry Louise Tyson, David Edward Ormonde Knight, Karine Jeannine Madeleine Hervé, Joanne Elizabeth Compson, Matthew Jon Timothy Page, Andrew Charles Payne, Nicola Louise Fisher, Brendon MacKenzie, Matthew Cox
  • Publication number: 20200291104
    Abstract: The invention relates to antibody molecules having specificity for TNF alpha, therapeutic uses of the antibody molecules and methods for producing said antibody molecules.
    Type: Application
    Filed: December 14, 2016
    Publication date: September 17, 2020
    Inventors: Ralph Adams, Pallavi Bhatta, Emma Dave, Sam Philip Heywood, Dave Paul Humphreys, Diane Marshall, Daniel John Lightwood
  • Patent number: 10775385
    Abstract: A new, stable trimeric TNF? structure is disclosed with distorted symmetry which can bind to the TNFR1 receptor to attenuate signalling therefrom, which can be used in the treatment and/or prevention of diseases associated with the soluble TNF?/TNFR1 interaction. Membrane-bound TNF? is not affected in its ability to signal through TNFR2, and thus the new structure of TNF? may be used in therapies which do not significantly raise the risk of infection or malignancy.
    Type: Grant
    Filed: October 22, 2015
    Date of Patent: September 15, 2020
    Assignee: UCB BIOPHARMA SRL
    Inventors: James Philip O'Connell, John Robert Porter, Alastair Lawson, Boris Kroeplien, Stephen Edward Rapecki, Timothy John Norman, Graham John Warrellow, Tracy Lynn Arakaki, Alex Buntin Burgin, William Ross Pitt, Mark Daniel Calmiano, David Andreas Schubert, Daniel John Lightwood, Rebecca Jayne Wootton
  • Patent number: 10766956
    Abstract: The present disclosure relates to TGF-beta antibodies and binding fragments thereof, DNA encoding the same, host cells comprising said DNA and methods of expressing the antibody or binding fragment in a host cell. The disclosure also extends to pharmaceutical compositions comprising the antibody or a binding fragment thereof and use of the antibody, binding fragment and compositions comprising the same in treatment of various diseases including fibrosis.
    Type: Grant
    Filed: June 7, 2017
    Date of Patent: September 8, 2020
    Assignee: UCB BIOPHARMA SRL
    Inventors: Helene Bon, Joanne Elizabeth Compson, Kate Louise Dixon, Carl Brendan Doyle, Mark Ellis, Maria Margarida Gouveia Sancho, Raymond Anthony Jupp, Lara Kevorkian, Daniel John Lightwood, Diane Marshall, Andrew Charles Payne, Joseph Michael David Rastrick, Monika-Sarah Schulze, Alison Turner, Kerry Louise Tyson
  • Publication number: 20200277366
    Abstract: The invention relates to multi-specific antibody molecules having specificity for TNF alpha, IL-17A and IL-17F, therapeutic uses of the antibody molecules and methods for producing said antibody molecules.
    Type: Application
    Filed: December 14, 2016
    Publication date: September 3, 2020
    Applicant: UCB Biopharma SPRL
    Inventors: Ralph ADAMS, Pallavi BHATTA, Emma DAVE, Sam Philip HEYWOOD, David Taul HUMPHERYS, Diane MARSHALL, Stevan Graham SHAW, Daniel John LIGHTWOOD
  • Patent number: 10752676
    Abstract: This present invention describes the derivation and selection of antibodies capable of neutralising the major exotoxins; TcdA and TcdB of Clostridium difficile. The invention also describes novel neutralisation and antigen binding properties of individual Mabs and mixtures thereof.
    Type: Grant
    Filed: September 10, 2012
    Date of Patent: August 25, 2020
    Assignee: UCB Biopharma SPRL
    Inventors: David Paul Humphreys, Daniel John Lightwood, Kerry Louise Tyson, David Edward Ormonde Knight, Karine Jeannine Madeleine Hervé, Joanne Elizabeth Compson, Matthew Jon Timothy Page, Andrew Charles Payne, Nicola Louise Fisher, Brendon Mackenzie, Matthew Cox
  • Publication number: 20190330327
    Abstract: It has been demonstrated that certain compounds bind to TNF and stabilise a conformation of trimeric TNF that binds to the TNF receptor. Antibodies which selectively bind to complexes of such compounds with TNF superfamily members are disclosed. These antibodies may be used to detect further compounds with the same activity, and as target engagement biomarker.
    Type: Application
    Filed: December 13, 2017
    Publication date: October 31, 2019
    Inventors: Alastair David Griffiths LAWSON, Daniel John LIGHTWOOD, Rebecca Jayne MUNRO, James Philip O'CONNELL, John Robert PORTER
  • Publication number: 20190330321
    Abstract: The present disclosure relates to TGF-beta antibodies and binding fragments thereof, DNA encoding the same, host cells comprising said DNA and methods of expressing the antibody or binding fragment in a host cell. The disclosure also extends to pharmaceutical compositions comprising the antibody or a binding fragment thereof and use of the antibody, binding fragment and compositions comprising the same in treatment of various diseases including fibrosis.
    Type: Application
    Filed: June 7, 2017
    Publication date: October 31, 2019
    Inventors: Helene BON, Joanne Elizabeth COMPSON, Kate Louise DIXON, Carl Brendan DOYLE, Mark ELLIS, Maria Margarida GOUVEIA SANCHO, Raymond Anthony JUPP, Lara KEVORKIAN, Daniel John LIGHTWOOD, Diane MARSHALL, Andrew Charles PAYNE, Joseph Michael David RASTRICK, Monika-Sarah SCHULZE, Alison TURNER, Kerry Louise TYSON
  • Publication number: 20180231562
    Abstract: A new, stable trimeric TNF? structure is disclosed with distorted symmetry which can bind to the TNFR1 receptor to attenuate signalling therefrom, which can be used in the treatment and/or prevention of diseases associated with the soluble TNF?/TNFR1 interaction. Membrane-bound TNF? is not affected in its ability to signal through TNFR2, and thus the new structure of TNF? may be used in therapies which do not significantly raise the risk of infection or malignancy.
    Type: Application
    Filed: October 22, 2015
    Publication date: August 16, 2018
    Inventors: James Philip O'CONNELL, John Robert PORTER, Alastair LAWSON, Boris KROEPLIEN, Stephen Edward RAPECKI, Timothy John NORMAN, Graham John WARRELLOW, Tracy Lynn ARAKAKI, Alex Buntin BURGIN, William Ross PITT, Mark Daniel CALMIANO, David Andreas SCHUBERT, Daniel John LIGHTWOOD, Rebecca Jayne WOOTTON